Seismic Therapeutic has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
Cambridge, Massachusetts-based Seismic is developing a pipeline of biologic drugs to treat immunological diseases based on its IMAPCT machine learning (ML) platform, which brings together structural biology, protein engineering, and translational immunology with the aim of speeding up the time to generate lead candidates.
